Loading...

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)

BACKGROUND: Sodium-glucose co-transporter-2 (SGLT2) inhibitors (gliflozins) are the newest class of medication available to treat type 2 diabetes (T2DM). Recent findings from the first complete cardiovascular safety trial in SGLT2 inhibitors, the Empagliflozin, Cardiovascular Outcomes, and Mortality...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Diabetes Ther
Main Authors: McGovern, Andrew, Feher, Michael, Munro, Neil, de Lusignan, Simon
Format: Artigo
Sprog:Inglês
Udgivet: Springer Healthcare 2017
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5380492/
https://ncbi.nlm.nih.gov/pubmed/28138853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-017-0229-8
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!